GSK Advances mRNA Flu Vaccine to Late-Stage Trial, Intensifying Competition for Moderna
MRNA has more than doubled off its 52-week low of $22.28.
Summary
GSK is moving its mRNA flu vaccine candidate into a late-stage trial after mid-stage data showed stronger immune responses than approved shots. The vaccine targets both haemagglutinin and neuraminidase, a dual-protein approach GSK says could improve protection and reduce transmission. This directly challenges Moderna's mFlusiva, which won FDA approval in August for adults 50 and older. GSK plans to start the trial this month, adding a major competitor in the mRNA flu space. Moderna's stock may face pressure as investors reassess its competitive moat in seasonal flu.
At the time of this announcement, MRNA was trading at $138.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56B. The 52-week trading range was $22.28 to $176.66. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.